IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Kitov Pharmaceutical Holdings Ltd. (“Kitov” or the “Company”) (Nasdaq: KTOV) concerning possible violations of federal securities laws.
If you purchased shares of Kitov and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
On February 6, 2017, the Israeli publication Calcalist disclosed that Kitov’s Chief Executive Officer, Isaac Israel, had been detained by the Israeli Securities Authority due to allegations of publishing misleading information regarding a recent clinical trial of one of Kitov’s products. When this information was announced to the public, the value of Kitov stock fell, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.